New evidence supports CBD for chronic TMD and bruxism pain :- Medznat
EN | RU
EN | RU

Help Support

By clicking the "Submit" button, you accept the terms of the User Agreement, including those related to the processing of your personal data. More about data processing in the Policy.
Back

Study explores cannabidiol's potential for orofacial and upper-quarter pain

Orofacial pain Orofacial pain
Orofacial pain Orofacial pain

What's new?

CBD effectively reduces chronic myofascial pain in conditions like TMDs and bruxism, especially when applied topically or intraorally, and may enhance the effects of conventional painkillers.

A systematic review published in "Journal of Clinical Medicine" highlighted cannabidiol’s (CBD) emerging role in mitigating pain and inflammation linked to upper-quarter disorders, including temporomandibular disorders (TMDs), orofacial pain, myofascial dysfunction, and post-dental surgery discomfort. The review analyzed 10 studies—ranging from randomized clinical trials to preclinical animal models—analyzing both the safety and effectiveness of CBD in these ailments.

The findings showed that CBD, a non-intoxicating compound derived from cannabis, may provide effective pain relief, particularly in chronic cases like myofascial TMDs and bruxism. Topical or intraoral application of CBD yielded the most promising results, with reported analgesic, anti-inflammatory, and muscle-relaxant benefits. Additionally, preclinical studies indicated that CBD could boost the effects of conventional painkillers such as opioids and NSAIDs, suggesting a synergistic role in pain management.

However, evidence on its effectiveness for acute pain, such as that following third molar extraction or pulpitis, was inconsistent. The review also identified substantial variability in CBD dosing, formulations, and outcome measures, which complicates direct comparison across studies. While clinical trials reported minimal side effects, safety data were often underreported, leaving gaps in long-term safety evaluation.

The authors conclude that while CBD shows considerable potential as an adjunct therapy for chronic upper-quarter pain conditions, especially those with a myofascial component, more rigorous and standardized clinical trials are necessary. These must focus on condition-specific outcomes, optimal dosing strategies, and delivery methods to establish clear clinical guidelines for CBD use.

Source:

Journal of Clinical Medicine

Article:

New evidence supports CBD for chronic TMD and bruxism pain

Authors:

Karolina Walczyńska-Dragon et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru
Try: